NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

5 equities research analysts have issued 1 year price targets for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.03 in the next twelve months. This suggests that the stock has a possible downside of 25.5%. View Analyst Price Targets for Achillion Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Headlines about ACHN stock have been trending positive on Friday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Achillion Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Achillion Pharmaceuticals.

Achillion Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 16,380,000 shares, an increase of 16.3% from the January 15th total of 14,080,000 shares. Based on an average daily volume of 3,710,000 shares, the short-interest ratio is currently 4.4 days. Currently, 12.0% of the company's shares are sold short. View Achillion Pharmaceuticals' Current Options Chain.

Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX), Edap Tms (EDAP) and ACADIA Pharmaceuticals (ACAD).

Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ARP Americas LP (5.37%), Magnetar Financial LLC (3.92%), State Street Corp (3.67%), Renaissance Technologies LLC (3.02%), UBS Group AG (2.76%) and CNH Partners LLC (2.26%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

ACHN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, Candriam Luxembourg S.C.A., Public Sector Pension Investment Board, South Dakota Investment Council, Bank of America Corp DE, Raymond James & Associates and Rafferty Asset Management LLC. Company insiders that have sold Achillion Pharmaceuticals company stock in the last year include David Scheer and Joseph Truitt. View Insider Buying and Selling for Achillion Pharmaceuticals.

ACHN stock was purchased by a variety of institutional investors in the last quarter, including ARP Americas LP, Magnetar Financial LLC, CNH Partners LLC, Boxer Capital LLC, Alliancebernstein L.P., Credit Suisse AG, State Street Corp and Fairmount Funds Management LLC. View Insider Buying and Selling for Achillion Pharmaceuticals.

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHN stock can currently be purchased for approximately $6.76.

Achillion Pharmaceuticals has a market capitalization of $946.72 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.